199
Participants
Start Date
April 12, 2016
Primary Completion Date
December 6, 2022
Study Completion Date
December 6, 2022
CMP-001
CMP-001 will be administered as per the dose and schedule specified in the respective arms.
Pembrolizumab
Pembrolizumab will be administered as per the schedule specified in the respective arms.
University of Pittsburgh, Pittsburgh
Thomas Jefferson University, Philadelphia
Fox Chase Cancer Center, Philadelphia
West Virginia University, Morgantown
University of Iowa Hospitals and Clinics, Iowa City
University of Colorado Cancer Center, Aurora
Banner MD Anderson Cancer Center, Phoenix
University of Arizona, Tucson
University of California, Los Angeles, Los Angeles
City of Hope National Medical Center, Duarte
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Georgetown, Washington D.C.
Dana Farber Cancer Institute, Boston
Regeneron Pharmaceuticals
INDUSTRY